



Ref: Syn/CS/SE/Reg 30/2024-25/Jan/07

Syngene International Limited
Biocon SEZ, Biocon Park, Plot No. 2 &
3, Bommasandra Industrial Area, IV
Phase, Jigani Link Road, Bengaluru
560 099, Karnataka, India
T +91 80 6891 8000
F +91 80 6775 8808
CIN: L85110KA1993PLC014937
www.syngeneintl.com

January 17, 2025

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Dear Sir/Madam,

Subject: Revised Intimation of Conference Call for Analysts and Investors

With reference to the intimation having reference no. Syn/CS/SE/Reg 30/2024-25/Jan/06 dated January 15, 2025, and in accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the revised intimation regarding the conference call due to non-functioning of the hyperlink provided for the pre-registration facility in the previous intimation, which now has been rectified.

We would like to confirm that all other details related to the conference call will remain as previously stated and unchanged.

The above-mentioned information will also be available on the website of the Company www.syngeneintl.com.

Request to kindly take this intimation on record.

Thanking You,

Yours faithfully,

For **SYNGENE INTERNATIONAL LIMITED**

Priyadarshini Mahapatra
Head Legal, Company Secretary & Compliance Officer



INVESTOR CONFERENCE CALL INVITE

Q3 FY 2024-25

Syngene's Q3 FY2025 Results Conference Call

At 6:00 pm IST on 23rd January 2025

The management team of Syngene International Limited ("Syngene") will organize a **conference call for Analysts and Investors on Thursday, 23rd January 2025 at 6.00 pm IST** following the announcement of financial results for the quarter ended December 31, 2024.

The call will be initiated with a brief management discussion on the Q3 FY2025 performance followed by an interactive Question & Answer session. Mr. Jonathan Hunt - Syngene's Managing Director and Chief Executive Officer and other members of the senior management team will represent Syngene on the conference call.

Details of the conference call are as under:

Date:	Thursday, 23rd January 2025
Time:	6:00 pm to 6:45 pm IST
Dial-in Numbers*	
Primary Number	+91 22 6280 1279 / 91 22 7115 8180
International Numbers	USA – 18667462133 UK – 08081011573 Singapore – 8001012045 Hong Kong – 800964448 Australia – 0080014243444
Pre-registration Facility (Diamond Pass™ link)	Step 1: Pre-register Click here . You will receive a passcode and a pin for the call on the registered email address. Step 2: Dial into the call on the Conference Call date, enter the passcode & pin as prompted. You will be directly connected to the call

*When using dial-in numbers mentioned please do so 10 minutes prior to the conference schedule to ensure that you are connected to your call in time

Syngene

Putting Science to Work

Confidentiality

Quality

Innovation

Science

INVESTOR CONFERENCE CALL INVITE

Q3 FY 2024-25

Replay/Audio Facility	Dial in numbers: +91 22 71945757 Playback ID: 83711 The replay facility will be available from 23rd January 2025 till 30 January 2025 The audio facility will also be available on the corporate website: https://syngeneintl.com/
Conference Call Transcript	Will be available within 7 working days of the call on the corporate website: https://syngeneintl.com/

About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE 398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's more than 5600 scientists offer both skills and the capacity to deliver great science, robust data security, and world class manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter, and Bristol-Myers Squibb as well as 2.2 Mn sq. ft of specialist discovery, development, and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK, Zoetis and Merck KGaA. For more details, visit www.syngeneintl.com For the Company's latest Environmental, Social, and Governance (ESG) report, visit <https://esgreport.syngeneintl.com>

For further information, please contact:

Krishnan G / Nandini Agarwal

P: +91 80 6891 9807

M: +919819992927 / 7838382527

E: krishnan.g@syngeneintl.com

E: nandini.agarwal@syngeneintl.com

Disclaimer: Certain of the statements that may be made or discussed at the conference call may be forward-looking statements and/or based on management's current expectations and beliefs concerning future developments and their potential effects upon Syngene International Limited (Syngene) and its associates. There can be no assurance that future developments affecting Syngene, and its associates will be those anticipated by management. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties and there are important factors that could cause actual results to differ, possibly materially, from expectations reflected in such forward-looking statements. Syngene does not intend, and is under no obligation, to update any forward-looking statement made at the conference call.